Diabetic kidney disease. (Q43721013)

26 November 2017

1 reference

title

Diabetic kidney disease. (English)

1 reference

26 November 2017

3

1 reference

26 November 2017

7

Peter Rossing

0 references

Merlin Thomas

object named as

Merlin C Thomas

1

0 references

Per-Henrik Groop

8

object named as

Per-Henrik Groop

1 reference

26 November 2017

6

Sophia Zoungas

1 reference

26 November 2017

Michael Brownlee

2

1 reference

26 November 2017

Kumar Sharma

4

1 reference

26 November 2017

Karin A M Jandeleit-Dahm

5

1 reference

26 November 2017

Mark E Cooper

9

1 reference

26 November 2017

30 July 2015

1 reference

Nature Reviews Disease Primers

26 November 2017

1 reference

26 November 2017

1

1 reference

26 November 2017

15018

1 reference

https://scigraph.springernature.com/pub.10.1038/nrdp.2015.18

26 November 2017

0 references

cites work

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Kidney disease and increased mortality risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Regression of microalbuminuria in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Temporal trends in the prevalence of diabetic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The changing natural history of nephropathy in type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Unchanged incidence of diabetic nephropathy in IDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Risks of rapid decline renal function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The management of diabetes in indigenous Australians from primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A clinical trial to maintain glycemic control in youth with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Chronic kidney disease: global dimension and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Albuminuria reflects widespread vascular damage. The Steno hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Pathogenesis, prevention, and treatment of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Phenotypic characteristics of diabetic kidney involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Hypoxia in diabetic kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The endothelium in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Molecular mechanisms of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Insulin signaling: implications for podocyte biology in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Podocyte structural parameters do not predict progression to diabetic nephropathy in normoalbuminuric type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Temporal profile of diabetic nephropathy pathologic changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Hyperglycemia and mechanical stress: targeting the renal podocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Nodular lesions and mesangiolysis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Structural-functional relationships in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Evidence for a novel TGF-beta1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Evolution of incipient nephropathy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Inflammation in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Glomerular size and structure in diabetes mellitus. I. Early abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Impaired tubular uptake explains albuminuria in early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Pathologic classification of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

UKPDS and the legacy effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Epigenetics: mechanisms and implications for diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Glycemic exposure, glycemic control, and metabolic karma in diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Serum lipids and the progression of nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Dysfunctional HDL takes its toll in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Selective versus total insulin resistance: a pathogenic paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The link between obesity and albuminuria: adiponectin and podocyte dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Towards understanding the inherited susceptibility for nephropathy in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Perceptions of epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Epigenome-wide association studies for common human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Prenatal environmental exposures, epigenetics, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A basis for accelerated progression of diabetic nephropathy in Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Birth weight and renal disease in Pima Indians with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Kidney volume, blood pressure, and albuminuria: findings in an Australian aboriginal community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Performance of the chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Cystatin C versus creatinine in determining risk based on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Measured GFR as "gold standard"--all that glitters is not gold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The assessment and management of albuminuria in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Comparison of different measures of urinary protein excretion for prediction of renal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Estimated albumin excretion rate versus urine albumin-creatinine ratio for the estimation of measured albumin excretion rate: derivation and validation of an estimated albumin excretion rate equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Derivation and validation of a renal risk score for people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Where are we in diabetic nephropathy: microRNAs and biomarkers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The potential for renoprotection with incretin-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Lowering blood pressure reduces renal events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The J-curve in arterial hypertension: fact or fallacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The pathogenesis and management of hypertension in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A practical approach to achieving recommended blood pressure goals in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effects of lowering LDL cholesterol on progression of kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effects of fibrates in kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Impact of weight change on albuminuria in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Dietary restriction and exercise for diabetic patients with chronic kidney disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Nutrition therapy recommendations for the management of adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Systematic review on urine albumin testing for early detection of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Association between estimated GFR, health-related quality of life, and depression among older adults with diabetes: the Diabetes and Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Maori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Does community-wide chronic kidney disease management improve patient outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Improving blood pressure control among adults with CKD and diabetes: provider-focused quality improvement using electronic health records

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Unrecognized anemia in patients with diabetes: a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The databases: renal replacement therapy since 1989--the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Emerging drugs for managing kidney disease in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Smoking in diabetic nephropathy: sparks in the fuel tank?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Mechanisms of diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Serum uric acid as a new player in the development of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

New insights into the use of biomarkers of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The multidimensional nature of renal disease: Rates and associations of albuminuria in an Australian Aboriginal community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Insulin Resistance and Microalbuminuria: A Cross-Sectional, Case-Control Study of 158 Patients With Type 2 Diabetes and Different Degrees of Urinary Albumin Excretion

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

21 January 2018

12 December 2020

Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Microalbuminuria as an early marker for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Changes in diabetes-related complications in the United States, 1990-2010

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Improved prognosis of diabetic nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Diabetic angiopathy: a specific vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Triopathy of diabetes; sequence of neuropathy, retinopathy, and nephropathy in one hundred fifty-five patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Measured GFR has limited clinical utility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

(9) Microvascular complications and foot care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Screening for chronic kidney disease in patients with diabetes: are we missing the point?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Diabetes: Assessing renal risk in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Origin and function of myofibroblasts in kidney fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.18

Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus

31 March 2020

1 reference

12 December 2020

Intensive glucose control and cardiovascular disease in type 2 diabetes--should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials

1 reference

12 December 2020

The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study).

1 reference

12 December 2020

Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.

1 reference

12 December 2020

1 reference

12 December 2020

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes

1 reference

12 December 2020

Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy

1 reference

12 December 2020

The impact of disadvantage on the development and progression of diabetic kidney disease.

1 reference

12 December 2020

Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.

1 reference

12 December 2020

Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease

1 reference

12 December 2020

Environmentally induced epigenetic transgenerational inheritance of phenotype and disease

1 reference

12 December 2020

Structural involvement in type 1 and type 2 diabetic nephropathy.

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease

1 reference

12 December 2020

Elevated blood pressure predicts the development of persistent proteinuria in the presence of poor glycemic control, in patients with type I diabetes

1 reference

12 December 2020

Glycaemic control and development of diabetic nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRDP.2015.18

1 reference

26 November 2017

1 reference